Boston Scientific(US:BSX) Di Yi Cai Jing·2025-11-09 09:37Core Insights - Multinational medical device companies are shifting from merely importing advanced global technologies to localizing their R&D efforts in China, aiming for a dual-driven model of global innovation and local manufacturing [1][4] Group 1: Localization Trends - The localization process of multinational medical device companies in China has accelerated significantly over the past eight years, with many companies reporting high levels of local R&D involvement [2][4] - GE Healthcare showcased that 60% of its newly launched innovative products at the expo were developed by Chinese teams, marking a record high for local R&D contributions [1][2] - Boston Scientific's Polaris intravascular ultrasound system was the first product approved under China's Medical Device Registration Holder (MAH) system, highlighting the company's commitment to local production [2] Group 2: Strategic Importance of China - China is recognized as a crucial strategic market for multinational companies, with a complete industrial system that supports the entire chain from R&D to mass production [3][4] - The Chinese government is actively optimizing the business environment and encouraging innovation, which serves as an accelerator for medical advancements [4] - Companies like Intuitive Surgical and Boston Scientific are investing in local production facilities and supply chains to enhance their responsiveness to domestic market demands [3][5] Group 3: Supply Chain Innovations - Boston Scientific is focusing on not just product line establishment but also on the localization of raw materials and key components, collaborating with local partners for joint R&D [5] - The company has received significant support from local regulatory bodies, which has facilitated the establishment of its manufacturing base in China [4][5] - The innovation capabilities of China's medical device supply chain are injecting new vitality into the global supply chain [5]